

*Contains Nonbinding Recommendations*

*Draft – Not for Implementation*

1 **Hydrogen Peroxide-Based Contact**  
2 **Lens Care Products: Consumer**  
3 **Labeling Recommendations -**  
4 **Premarket Notification (510(k))**  
5 **Submissions**  
6

---

7 **Draft Guidance for Industry and**  
8 **Food and Drug Administration Staff**  
9

10 ***DRAFT GUIDANCE***  
11

12 **This draft guidance document is being distributed for comment purposes**  
13 **only.**  
14

15 **Document issued on August 17, 2022.**  
16

17 You should submit comments and suggestions regarding this draft document within 60 days of  
18 publication in the *Federal Register* of the notice announcing the availability of the draft  
19 guidance. Submit electronic comments to <https://www.regulations.gov>. Submit written  
20 comments to the Dockets Management Staff, Food and Drug Administration, 5630 Fishers Lane,  
21 Room 1061, (HFA-305), Rockville, MD 20852. Identify all comments with the docket number  
22 listed in the notice of availability that publishes in the *Federal Register*.  
23

24 For questions about this document, contact the OHT1: Office of Ophthalmic, Anesthesia,  
25 Respiratory, ENT and Dental Devices/DHT1A: Division of Ophthalmic Devices at (301) 796-  
26 5620.  
27  
28  
29  
30



32 U.S. Department of Health and Human Services  
33 Food and Drug Administration  
34 Center for Devices and Radiological Health  
35

## **Preface**

36

37

### **Additional Copies**

39

40 Additional copies are available from the Internet. You may also send an e-mail request to  
41 [CDRH-Guidance@fda.hhs.gov](mailto:CDRH-Guidance@fda.hhs.gov) to receive a copy of the guidance. Please include the document  
42 number 18041 and complete title of the guidance in the request.

43

DRAFT

*Contains Nonbinding Recommendations*

*Draft – Not for Implementation*

44 **Table of Contents**

45

46 I. Introduction ..... 1

47 II. Background ..... 2

48 III. Scope ..... 3

49 IV. Specific Consumer Labeling Recommendations..... 4

50 A. General Considerations ..... 4

51 B. Suggested Format and Content of Consumer Labeling ..... 5

52 (1) Package Insert Labeling ..... 5

53 (2) Carton Labeling..... 10

54 (3) Bottle Labeling..... 12

55 Appendix A: Package Insert Labeling Example ..... 14

56 Appendix B: Carton Labeling Example..... 21

57 Appendix C: Sample Bottle Labeling ..... 23

58

DRAFT

59  
60 **Hydrogen Peroxide-Based Contact**  
61 **Lens Care Products: Consumer**  
62 **Labeling Recommendations -**  
63 **Premarket Notification (510(k))**  
64 **Submissions**  
65

---

66 **Draft Guidance for Industry and**  
67 **Food and Drug Administration Staff**  
68

69 *This draft guidance, when finalized, will represent the current thinking of the Food and Drug*  
70 *Administration (FDA or Agency) on this topic. It does not establish any rights for any person*  
71 *and is not binding on FDA or the public. You can use an alternative approach if it satisfies*  
72 *the requirements of the applicable statutes and regulations. To discuss an alternative*  
73 *approach, contact the FDA staff or Office responsible for this guidance as listed on the title*  
74 *page.*

75 **I. Introduction**

76 FDA is issuing this draft guidance to provide labeling recommendations for hydrogen peroxide-  
77 based contact lens care products (HPCPs) submitted in premarket notification (510(k))  
78 submissions. These labeling recommendations are important because misuse associated with  
79 these devices has resulted in serious eye injuries. FDA believes that the labeling  
80 recommendations in this guidance may help manufacturers develop labeling with information  
81 about specific risks and directions for use of the HPCPs in conjunction with a user's prescribed  
82 contact lenses. These labeling recommendations are intended to promote the safe and effective  
83 use of HPCPs and ensure that consumers receive and understand information regarding the  
84 benefits and risks associated with the use of the device.

85  
86 The contents of this document do not have the force and effect of law and are not meant to bind  
87 the public in any way, unless specifically incorporated into a contract. This document is intended  
88 only to provide clarity to the public regarding existing requirements under the law. FDA  
89 guidance documents, including this guidance, should be viewed only as recommendations, unless  
90 specific regulatory or statutory requirements are cited. The use of the word *should* in Agency  
91 guidance means that something is suggested or recommended, but not required.

92

## 93 **II. Background**

94

95 Hydrogen peroxide-based contact lens care product solutions, as well as other multipurpose  
96 solutions, both clean and disinfect contact lenses by breaking up and helping to remove trapped  
97 debris, protein, fatty deposits, and microorganisms. Unlike other multipurpose solutions,  
98 hydrogen peroxide-based contact lens care product solutions are generally preservative-free,  
99 which makes them a suitable option for those who are allergic or sensitive to the preservatives  
100 found in multipurpose solutions. They are not risk-free, however, and should be used by  
101 following appropriate labeling considerations.<sup>1</sup> Consumers should be aware of these  
102 considerations prior to choosing, and while using, this type of medical device.

103

104 To implement section 520(*l*) of the Federal Food, Drug, and Cosmetic (FD&C) Act, which  
105 contains specific provisions on transitional devices (i.e., those devices regulated as drugs before  
106 the Medical Device Amendments of 1976 became law), FDA published a rule proposing to  
107 reclassify HPCPs from class III (premarket approval) to class II (special controls).<sup>2</sup> The final rule  
108 reclassifying HPCPs published on June 6, 1997,<sup>3</sup> amending 21 CFR 886.5918 and 21 CFR  
109 886.5928 to classify rigid gas permeable contact lens care products and soft contact lens care  
110 products as class II, respectively. FDA also issued a guidance document, “[Premarket Notification](#)  
111 [\[510\(k\)\] Guidance Document for Contact Lens Care Products](#),”<sup>4</sup> and a subsequent addendum  
112 “[Contact Lens Care Products Labeling](#).”<sup>5</sup> These documents include details regarding, among  
113 other things, the labeling of contact lens care products.

114

115 The safety and effectiveness of HPCPs when used as directed has been well established in the  
116 last few decades; however, FDA has become aware of an increase in the number of adverse  
117 event reports related to the misuse of these products. Consumers have reported adverse events  
118 ranging from irritation to severe burning and stinging of the eyes and even blindness with the use  
119 of HPCPs. The reports received to date indicate that the packaging is not easily distinguishable  
120 from other lens care products, which FDA believes has likely resulted in improper use. FDA  
121 convened a meeting of the Ophthalmic Devices Panel of the Medical Devices Advisory  
122 Committee and the Risk Communication Advisory Committee on March 17, 2017, to discuss  
123 additional measures to mitigate the potential risk for misuse of these devices.<sup>6</sup> While the rate of

---

<sup>1</sup> For further information on hydrogen peroxide-based contact lens care products, see  
<https://www.fda.gov/medical-devices/contact-lenses/hydrogen-peroxide-solution>.

<sup>2</sup> See 62 FR 14277 (April 1, 1996). With the enactment of the Medical Device Amendments of 1976, transitional devices were classified in class III by operation of the statute, unless later classified by FDA in class I or II. See FD&C Act § 520(*l*)(1).

<sup>3</sup> See 62 FR 30985.

<sup>4</sup> <https://www.fda.gov/medical-devices/guidance-documents-medical-devices-and-radiation-emitting-products/contact-lens-care-products-premarket-notification-510k-guidance>.

<sup>5</sup> <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/contact-lens-care-products-labeling>.

<sup>6</sup> March 17, 2017 Meeting: Ophthalmic Devices Panel for the Medical Devices Advisory Committee and the Risk Communication Advisory Committee (available at <https://www.fda.gov/advisory-committees/ophthalmic-devices-panel/2017-meeting-materials-ophthalmic-devices-panel>).

## *Contains Nonbinding Recommendations*

### *Draft – Not for Implementation*

124 adverse events reported to the FDA is relatively low compared to the estimated number of HPCP  
125 users, the number of reports likely underestimate the actual occurrence of such events. The  
126 meeting covered a range of important issues, including appropriate labeling and packaging of  
127 these products, and the importance of clearly communicating the risks of misuse to the consumer  
128 public. The Panel emphasized a need for simplicity and clear messaging in terms of warnings  
129 and instructions for use, in addition to the ability to identify the bottles by utilizing a red tip and  
130 red cap as already used on most HPCP solutions. The Panel also recommended a redesign and  
131 standardization of the labeling so that it is different from other contact lens care products. In light  
132 of the well-documented low compliance rate among consumers with recommended lens care  
133 practices,<sup>7</sup> as well as the reasons outlined above, FDA is providing recommendations concerning  
134 the content and format of labeling for these devices. FDA believes the labeling content and  
135 format recommended in this guidance provides at least the same level of protection of the public  
136 health and safety as the labeling details contained in “[Premarket Notification \[510\(k\)\] Guidance](#)  
137 [Document for Contact Lens Care Products](#)”<sup>8</sup> and its addendum “[Contact Lens Care Products](#)  
138 [Labeling](#).”<sup>9</sup>

### 139 **III. Scope**

140 This guidance document applies to all HPCPs. These devices are classified under 21 CFR  
141 886.5918 and 21 CFR 886.5928 with the product codes listed in the table below:  
142  
143

**Table 1: Applicable Product Codes**

<b>Product Code</b>	<b>Product Code Name</b>	<b>Regulation Number</b>
MRC	Products, Contact Lens Care, Rigid Gas Permeable	21 CFR 886.5918
LPN	Accessories, Soft Lens Products	21 CFR 886.5928

144 Although not in the scope of this guidance, the Panel also suggested making a change in the  
145 bottle shape, size, color, tactile features or other characteristics that would distinguish HPCPs  
146 from other contact lens care products that do not contain hydrogen peroxide. While FDA does  
147 not intend to recommend the type of bottle to be used to contain HPCP solutions, FDA  
148 recommends, to the extent possible, containers should appear distinct from those of multipurpose  
149 solutions or other products without hydrogen peroxide, which could minimize potential product  
150 selection errors and product misuse.  
151

152  
153 Based on the adverse event reports and feedback obtained during the March 2017 Panel Meeting,  
154 device misuse may be exacerbated if the directions for use and warnings or precautions in the  
155 device labeling are not clear. FDA believes that these problems can be mitigated by emphasizing  
156 and simplifying important warnings and directions for use on the bottle and carton labeling for  
157 HPCP solutions. The inclusion of such information should also be helpful in developing labeling  
158 with adequate information for use under 21 CFR 801.5. For example, FDA believes the

<sup>7</sup> Ky W, Scherick K, Stenson S. Clinical survey of lens care in contact lens patients. CLAO J. 1998 Oct;24(4):216-9.

<sup>8</sup> <https://www.fda.gov/medical-devices/guidance-documents-medical-devices-and-radiation-emitting-products/contact-lens-care-products-premarket-notification-510k-guidance>.

<sup>9</sup> <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/contact-lens-care-products-labeling>.

## *Contains Nonbinding Recommendations*

### *Draft – Not for Implementation*

159 appropriate design and standardization of labeling would help inform consumers of device risks,  
160 thereby increasing the likelihood of appropriate device use and helping to mitigate against device  
161 misuse.  
162

163 Since these recommendations are based on known safety issues, FDA recommends that this  
164 information be considered for inclusion as current product labeling is updated, and that labeling  
165 included as part of future premarket submissions for HPCPs incorporate the recommendations.  
166 For currently marketed HPCPs, manufacturers should evaluate their labeling changes according  
167 to FDA’s guidance, “[Deciding When to Submit a 510\(k\) for a Change to an Existing Device](#).”<sup>10</sup>  
168

169 This guidance is not intended to include a complete listing of all labeling components for  
170 HPCPs. This guidance should be used as a complement to FDA’s “[Guidance on Medical Device  
171 Patient Labeling](#),”<sup>11</sup> (hereafter referred to as the “Patient Labeling guidance,” which describes  
172 FDA’s current thinking on making medical device patient labeling understandable to and usable  
173 by patients), existing regulations, and other relevant guidance documents containing additional  
174 labeling recommendations. This guidance also complements FDA’s guidance “[Premarket  
175 Notification \[510\(k\)\] Guidance Document for Contact Lens Care Products](#)”<sup>12</sup> and its addendum  
176 “[Contact Lens Care Products Labeling](#).”<sup>13</sup> This guidance provides recommendations that are  
177 specific to HPCPs and may assist in complying with some special controls.

## 178 **IV. Specific Consumer Labeling Recommendations**

### 179 **A. General Considerations**

180 Contact lens care products, including HPCPs, are subject to the general labeling requirements for  
181 all medical devices outlined in 21 CFR 801. The premarket notification submission must include  
182 proposed labeling in sufficient detail to satisfy the requirements of 21 CFR 807.87(e). Consumer  
183 labeling for HPCPs includes information contained on the package insert, carton, and bottle, and  
184 is directed to the contact lens wearer. The consumer labeling for HPCPs should instruct the  
185 consumer on product care to ensure contact lenses are used safely and effectively, to identify  
186 potential risks and benefits, and to explain what to expect when these care products are used. The  
187 labeling should contain sufficient information to describe the device, its intended use,  
188 precautions, warnings, and contraindications.  
189

190 Consumer labeling should be written in simple, plain language that does not exceed the eighth-  
191 grade reading level. Regardless of the reading level, poorly designed text can still be confusing  
192 and misleading. The consumer labeling should be directed to users and potential consumers of  
193 HPCPs and should address the following questions:

---

<sup>10</sup> <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/deciding-when-submit-510k-change-existing-device>.

<sup>11</sup> <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-medical-device-patient-labeling>.

<sup>12</sup> <https://www.fda.gov/medical-devices/guidance-documents-medical-devices-and-radiation-emitting-products/contact-lens-care-products-premarket-notification-510k-guidance>.

<sup>13</sup> <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/contact-lens-care-products-labeling>.

*Contains Nonbinding Recommendations*

*Draft – Not for Implementation*

194  
195  
196  
197  
198  
199  
200

- How do Hydrogen Peroxide-Based Contact Lens Care Products work?
- How should I use Hydrogen Peroxide-Based Contact Lens Care Products correctly?
- What are the risks associated with Hydrogen Peroxide-Based Contact Lens Care Product use?
- Who should I contact if there is a problem?

201 The lay language should provide a balanced presentation of adverse events and the risks and  
202 benefits of the device. It should not introduce implied or actual statements regarding performance  
203 that are unsubstantiated or that may be misleading to consumers. In order to increase the  
204 likelihood that the consumer labeling is read and understood by the consumer, we recommend  
205 that manufacturers consider placing consumer labeling on their website to help consumers obtain  
206 the most up-to-date information.

207  
208 We recommend that consumer labeling contain the information in the sections outlined in the  
209 [Patient Labeling guidance](#). The sections suggested in the [Patient Labeling guidance](#) may be  
210 adapted as appropriate for HPCPs and should enable the consumer to easily find and understand  
211 information that answers the questions identified above. The recommendations in this draft  
212 guidance are intended to supplement and enhance the information that is often already identified  
213 in labeling for these device types. To the extent the recommendations in this document depart  
214 from previously issued recommendations in the 2010 guidance, “[Contact Lens Care Products](#)  
215 [Labeling](#),”<sup>14</sup> this document supersedes those previous recommendations as applied to hydrogen  
216 peroxide-based contact lens care products under product codes MRC and LPN. This guidance  
217 presents FDA’s format and content recommendations for specific labeling components, and FDA  
218 has provided examples of each in the appendices to help illustrate the recommendations.

219 **B. Suggested Format and Content of Consumer Labeling**

220 **(1) Package Insert Labeling**

221 To help manufacturers develop appropriate labeling and to mitigate the safety issues related to  
222 HPCP misuse, FDA is providing the following recommendations for the package insert labeling.  
223 The package insert should include the following information where applicable. An example of  
224 package insert labeling is provided in Appendix A.

225  
226

**a. General Instructions and Description**

227 FDA believes that the package label insert should include general instructions and description as  
228 outlined below:

229  
230  
231  
232  
233

- A section that describes the general process involved with the use of HPCPs including: a description of the disinfecting and neutralization process, and whether it is a one-step or two-step process.
- A statement to read the instructions carefully and to retain the information for future use.

---

<sup>14</sup> <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/contact-lens-care-products-labeling>.

## *Contains Nonbinding Recommendations*

### *Draft – Not for Implementation*

- 234
- 235
- 236
- 237
- 238
- 239
- 240
- 241
- 242
- 243
- The trade name and identification of the active ingredient(s) (optional, list of inactive ingredients), sterility status, and when applicable, a description of the contents (e.g., case, disk or tablet) and any additional components. FDA believes that prominent text identifying that the product contains 3% hydrogen peroxide should be included in this section.
  - A description of the function of the device (i.e., how the device works in relation to the contact lenses). When applicable, the actions may also be listed with the indications for use.
  - The indications for use statement as described in the submission.

#### **b. Contraindications**

244

245

246

247

248

249

250

251

Contraindications describe situations in which the device should not be used because the risk of use of the device clearly outweighs any reasonably foreseeable benefit. FDA recommends that manufacturers include all contraindications specific to the device. For example, such contraindications may include a statement identifying that the device should not be used if allergic to any ingredient in the device. If there are no contraindications, a statement may be provided noting that there are no known contraindications.

#### **c. Warnings**

252

253

254

255

256

257

258

259

260

FDA recommends that manufacturers prominently display (e.g., using emphasized text) appropriate warnings regarding how to avoid known hazards associated with the use of HPCPs. These warnings may alert consumers to the possibility of serious adverse reactions, situations which, if not avoided, could result in death or serious injury, and steps that should be taken if they occur. FDA believes such warnings include the following examples of (1) general warnings that should be prominently listed in all labeling types (package insert labeling, carton labeling, and bottle labeling) and (2) additional warnings that should be included in the package insert.

#### **General Warnings**

261

262

263

FDA believes general warnings should include the following information:

- 264
- 265
- 266
- 267
- 268
- 269
- 270
- 271
- 272
- 273
- 274
- A statement that the solution should only be used with the case provided and warn against the use of flat lens cases.
  - A statement identifying the minimum time to ensure the completion of the neutralization process prior to lens insertion and a statement that unneutralized disinfecting solution should not be put into the eye.
  - Directions for when unneutralized solution does come in contact with the eyes.
  - A statement that warns against the reuse of the neutralized HPCP solutions.
  - A statement that warns against rinsing your lenses with the HPCP solution, which would cause severe burning or stinging.
  - A statement that warns against squirting the HPCP solution into the eyes.

275

276

277

The statements above, wherever possible, should also warn consumers of the risks associated with inserting HPCP solution into the eye (e.g., severe burning and stinging).

#### **Additional Warnings**

278

## *Contains Nonbinding Recommendations*

### *Draft – Not for Implementation*

279 FDA recommends that manufacturers include warnings emphasizing that it is essential for  
280 consumers to follow all labeling instructions for proper use of contact lenses and lens care  
281 products. FDA recommends such additional warnings include the following instructions for use  
282 and warnings pertaining to contact lens wear:

- 283
- 284 • A statement warning against reuse or “topping off solutions.” Reuse may reduce effective  
285 lens disinfection and could lead to severe infection, vision loss, or blindness. “Topping  
286 off” is the addition of fresh solution to solution that has been sitting in the lens case. A  
287 statement referencing the use of fresh, sterile or unexpired solution each time you use  
288 your contact lenses should be included. Graphics warning against reuse or topping off of  
289 solution are also recommended.
- 290 • A statement against storing your lenses or rinsing your lens case with water or any non-  
291 sterile or expired saline solution (e.g., these practices may lead to ocular infections).
- 292 • A statement that warns against risks associated with contact lens exposure to water from  
293 showering, swimming in pools, lakes, or oceans (e.g., may harbor microorganisms that  
294 lead to severe infection, vision loss, or blindness).
- 295 • A statement that warns against using inappropriate liquids to disinfect your lenses, since  
296 not using the recommended disinfectant may lead to severe infection, vision loss or  
297 blindness.
- 298 • A statement that warns of the risks associated with using solutions past their discard date  
299 since the performance of solutions have not be tested past their discard date. The discard  
300 date refers to the time you can safely use the contact lens care product after the bottle has  
301 been opened. It is not the same as the shelf-life/expiration date, which is the last date that  
302 the product is still effective before it is opened.
- 303 • A statement that warns of the potential contamination of the solution, which may reduce  
304 the effectiveness of solutions and result in contamination of lenses (e.g., avoid touching  
305 surfaces or transferring solutions).
- 306 • A statement that warns of the risks associated with ingestion of hydrogen peroxide, which  
307 may occur if small children have access to the product. A statement should be added  
308 advising consumers to seek immediately medical attention if ingested and/or promptly  
309 contact their eye care practitioner.
- 310 • When applicable, a statement that warns of possible effects associated with rubbing rigid  
311 gas permeable (RGP) lenses with peroxide solution (e.g., that may result in skin  
312 discoloration). A statement should be added advising consumers to wash and rinse their  
313 hands after rubbing RGP lenses.
- 314 • When applicable, a statement that warns against ingestion of neutralizing tablets that may  
315 result in upset stomach and vomiting. A statement should be added advising consumers  
316 not to ingest tablets and to seek immediately medical attention if ingested and/or  
317 promptly seek medical assistance or a poison control center.
- 318 • When applicable, statements against improper use of neutralization tablets that may result  
319 in inadequate neutralization. Statements should be added advising consumers of  
320 situations that may result in inadequate neutralization or disinfection (e.g., crushing a  
321 neutralizing tablet, number of times a neutralizer disk may be used).
- 322

### **Non-Product Specific Warning**

## *Contains Nonbinding Recommendations*

### *Draft – Not for Implementation*

324 Additionally, FDA recommends that manufacturers include a non-product specific warning that  
325 specifies that consumers should follow the directions of the eye care practitioner and all labeling  
326 instructions for proper use and care of both their lenses and lens care products, including the lens  
327 case since problems with contact lenses and lens care products could result in serious injury to  
328 the eye. FDA recommends that this warning also include the following information:

- 329 • Specifying that daily wear lenses are not indicated for overnight wear and that clinical  
330 studies have shown that there is an increased risk for serious adverse reactions when  
331 worn overnight.
- 332 • Specifying that extended wear lenses should be regularly removed for cleaning and  
333 disinfection or disposal and replacement as prescribed by the eye care practitioner, and  
334 that clinical studies have shown that there is an increased incidence of serious adverse  
335 reaction in extended wear contact lens wearers compared to daily wear contact lens  
336 wearers. Studies have also shown that the risk of serious adverse reactions increases the  
337 longer extended wear lenses are worn before removal for cleaning and disinfection or for  
338 disposal and replacement.
- 339 • Specifying that studies have also shown that smokers who wear contact lenses have a  
340 higher incidence of adverse reactions.
- 341 • Specifying that if the consumer experiences eye discomfort, excessive tearing, vision  
342 changes, or redness of the eye, that they should remove their contact lenses and contact  
343 their eye care practitioner.  
344

#### **d. Precautions**

346 FDA recommends that precautions include information for the safe and effective use of the  
347 device by the consumer to mitigate minor or moderate injury. Listed below are examples of  
348 general precautions that pertain to all HPCP solutions and specific precautions for neutralizing  
349 products. FDA believes such precautions include the following:

350

#### **General Precautions**

- 352 • A statement that consumers should always wash and dry their hands prior to  
353 manipulating lenses because residual dirt, oils, and/or contamination may result in  
354 subsequent stinging or ocular infection.
- 355 • A statement that consumers should never use generic hydrogen peroxide not specifically  
356 intended for use with contact lenses or mix HPCP solutions because this may result in  
357 insufficient disinfection, neutralization, and/or damage to contact lenses.
- 358 • Statements that consumers should never reuse solutions, should always use fresh,  
359 unexpired solution, and should never store lenses in used neutralized solution for more  
360 than 24 hours because this will help ensure sufficient disinfection.
- 361 • Statements regarding activities during or after use of HPCP solutions that may reduce the  
362 product effectiveness, enhance deterioration and/or cause lens damage. These activities  
363 may include: shaking/inverting the lens case during disinfection, failure to discard the  
364 contents of the bottle “X” months after first opening, failure to keep the bottle closed  
365 when not in use, failure to store the bottle at a certain temperature and/or range, failure to  
366 keep the lenses immersed in the storage solution when not worn; and heating the solution  
367 or contact lenses.  
368

## *Contains Nonbinding Recommendations*

### *Draft – Not for Implementation*

#### 369 **Precautions for Neutralizing Products**

370 FDA recommends the inclusion of statements regarding activities during or after use of  
371 neutralizing tablets that may reduce the product effectiveness, enhance deterioration and/or cause  
372 lens damage. These activities may include: using tablets that appear to be broken, chipped, or  
373 discolored; using tablets from packages that are torn or punctured; substituting neutralizing  
374 components; and using neutralizing tablets in a heat disinfection unit.

375

#### 376 **e. Adverse Reactions**

377 FDA recommends that the package insert labeling should inform consumers about the potential  
378 adverse reactions associated with the use of the product and that eye problems, including corneal  
379 ulcers, can develop rapidly and lead to loss of vision. The package insert labeling should also  
380 include a statement that if a consumer notices any adverse reactions (e.g., stinging and burning,  
381 eye discomfort, excessive tearing, among others), they should immediately remove lenses.  
382 Statements should be added to the package insert advising the consumer on instructions for lens  
383 removal thereby reducing the potential for ocular damage. The package insert labeling should  
384 also include statements that consumers immediately contact their eye care practitioner if  
385 problems persist or worsen, to seek immediate professional care, and to report all adverse events  
386 to the manufacturer. A statement should be added to inform the consumer that they can also  
387 report adverse events to FDA Medwatch. This is important to diagnose or document any adverse  
388 events associated with the product.

389

#### 390 **f. General Directions for Use**

391 FDA recommends all directions for use contain the major steps of the process (e.g., rinse with  
392 solution, fill provided container, and soak) to ensure proper use of HPCP solutions. Each step  
393 should be briefly described using simple language for easy understanding. The use of graphics in  
394 device labeling has been shown to contribute to better comprehension.<sup>15</sup> As such, FDA  
395 recommends that simple graphics, where appropriate, should be included. In order to provide a  
396 complete set of directions for consumers, FDA recommends that these directions include the  
397 following:

- 398 • Instructions for safe handling of contact lenses to minimize residual dirt, oils, and/or  
399 contamination, which may result in subsequent stinging or ocular infection.
- 400 • Specific, detailed directions based on the lens type (e.g., soft and RGP lenses) to convey  
401 important differences in the cleaning/disinfection regimen. FDA recommends  
402 reemphasizing warning statements regarding not putting HPCP solution into the eye  
403 because unneutralized hydrogen peroxide exposure may result in corneal burns, redness  
404 and stinging (see Appendix A for examples for soft lenses and for RGP lenses).
- 405 • Information for lens case care and replacement. This is important to ensure that users  
406 appropriately clean and care for the lens case as they have been shown to be a source of  
407 microbial contamination.
- 408 • Information regarding how the product is supplied (e.g., sterile, quantity of contents, type  
409 of packaging, lot number), distributor/manufacturer name and address, and the date the

---

<sup>15</sup> Kools M, van de Wiel MW, Ruiter RA, Kok G. Pictures and text in instructions for medical devices: effects on recall and actual performance. *Patient Educ Couns*. 2006 Dec;64(1-3):104-11. Epub 2006 Feb 10.

## *Contains Nonbinding Recommendations*

### *Draft – Not for Implementation*

410 labeling was printed. This is important to allow traceability and identification for adverse  
411 event reporting or for consumer questions.

## 412 **(2) Carton Labeling**

413 In order to highlight warnings, precautions, and to minimize crowding, FDA recommends that the  
414 directions for use should not be included in carton labeling. However, a statement should be  
415 added directing users to follow directions on the bottle and in the package insert. FDA also  
416 recommends that the carton labeling contain a red banner (e.g., at least 1 inch in height)  
417 encircling the top of the carton that includes text emphasizing that the HPCP solution should not  
418 be put into the eyes. We also recommend that manufacturers include two identical statements,  
419 such as “DO NOT PUT IN EYES,” that span the circumference of the bottle with associated  
420 graphics, in emphasized font. The banner should be similar to the banner placed on the bottle.  
421 FDA recommends a minimalist approach to the content of the carton labeling and font sizes  
422 consistent with the [Patient Labeling guidance](#), which aligns with 2017 Panel recommendations.  
423 An example of carton labeling is provided in Appendix B.

### 425 **a. Manufacturer and product information**

426 HPCPs are over-the-counter devices and labeling must comply with 21 CFR 801.60 - Principal  
427 display panel, as well as 21 CFR 801.61 - Statement of identity, 21 CFR 801.62 - Declaration of  
428 net quantity of contents. In addition, the labeling must comply with 21 CFR 800.12 – Contact lens  
429 solutions and tablets; tamper-resistant packaging, and 21 CFR 800.10 – Contact lens solutions;  
430 sterility, and should also contain the following recommended information:

431 Principal Display Panel (*see* 21 CFR 801.60):

- 433 • Product Trade Name [including emphasis on “3% Hydrogen Peroxide [Solution]”  
434 (e.g., in prominent text)] (*see* [Patient Labeling guidance](#) for recommendations on  
435 font sizes for Headings)
- 436 • Actions and Indications (*see* 21 CFR 801.61; e.g., cleans, disinfects)
- 437 • Lens Compatibility (i.e., the type of lenses for which the device may be used)
- 438 • Net Quantity Contents (21 CFR 801.62)
- 439 • Sterile

440 Outer Carton Panels

- 442 • Special Storage Conditions (e.g., store at room temperature)
- 443 • A statement referring customers to the bottle and package insert for information on  
444 proper use of the product
- 445 • Tamper-Resistant Statement (21 CFR 800.12)
- 446 • A statement to keep product out of the reach of children
- 447 • [Insert information on whom to contact for concerns, adverse reactions, and  
448 additional information: [Distributed by/Manufactured by/Manufactured for] Address  
449 including zip code, website, and phone number.]
- 450 • Lot Number
- 451 • Expiration Date
- 452 • Product Information:

## *Contains Nonbinding Recommendations*

### *Draft – Not for Implementation*

- 453 ○ Description (i.e., Active Ingredients)
- 454 ○ Package contents (e.g., a lens case is included)
- 455 ● A statement referring customers to consult the package insert for complete safety
- 456 information
- 457 ● Website and social media connections (e.g., Quick Response (QR) code, website link)
- 458 to manufacturers and FDA (e.g., “Hydrogen Peroxide Solution”
- 459 <https://www.fda.gov/medical-devices/contact-lenses/hydrogen-peroxide-solution>)
- 460

#### **b. Contraindications**

461 FDA recommends that the same contraindications that are included in the package insert labeling  
462 as outlined in Section IV.B.1.b of this guidance also be included on the carton labeling.

#### **c. Warnings**

466 To minimize overcrowding, FDA recommends that manufacturers include only those warnings  
467 statements in the carton labeling that inform the consumers of the risks associated with HPCP  
468 solution that is not neutralized. This is important because unneutralized hydrogen peroxide  
469 exposure may result in corneal burns, redness and stinging. Statements using emphasized text  
470 (e.g., red and bold text) should be added to the warnings section on the carton to highlight these  
471 concerns, but bold text should be limited to emphasize key details only. In addition, FDA  
472 recommends that consumers be referred to the package insert for a complete list of warnings.  
473 Manufacturers should include the following statements/warnings with associated graphics on the  
474 carton labeling to inform consumers of the risks associated with unneutralized hydrogen  
475 peroxide:

- 476 ● A statement that the solution should only be used with the case provided and warn
- 477 against the use of flat lens cases.
- 478 ● A statement identifying the minimum time to ensure the completion of the neutralization
- 479 process prior to lens insertion.
- 480 ● A statement that warns against rinsing your lenses with the HPCP solution, which would
- 481 cause severe burning or stinging.
- 482 ● A statement that warns against squirting the HPCP solution into the eyes.
- 483 ● The statements above, wherever possible, should also warn the consumer of the risks
- 484 associated with inserting HPCP solution into the eye (e.g., severe burning and stinging).
- 485 ● A statement that the product contains hydrogen peroxide and that users should follow all
- 486 directions on the bottle and in the package insert to avoid injury.
- 487
- 488

489 Since most non-hydrogen peroxide contact lens care products are used with flat lens cases that  
490 do not neutralize hydrogen peroxide, consumers may be confused regarding the need for the  
491 special neutralizing case provided with HPCP solutions. Therefore, to increase the likelihood that  
492 consumers understand these risks, and to emphasize the need for the neutralization of hydrogen  
493 peroxide, FDA recommends manufacturers include additional warnings, including graphics,  
494 against the use of flat lens cases on the top left and right carton flaps (in emphasized text), in  
495 addition to the body of the carton labeling. This labeling recommendation is consistent with the

## *Contains Nonbinding Recommendations*

### *Draft – Not for Implementation*

496 2017 Panel recommendations, which advised graphics on the opening flap of the box since this  
497 warning is the first message consumers encounter as they open the product.

498

499

#### **d. Precautions**

500 FDA recommends that carton labeling only include precautions for the safe use of the device by  
501 the user to mitigate minor or moderate injury. These may include precautions that warn against  
502 the use of generic hydrogen peroxide or activities that may result in inadequate neutralization of  
503 hydrogen peroxide prior to use. FDA recommends that manufacturers should include a  
504 statement that refers consumers to the package insert for a complete list of precautions.

505

### **(3) Bottle Labeling**

506 To help manufacturers develop bottle labeling that is clear, simple and consistent across products  
507 and to help mitigate the safety issues for HPCPs, FDA is providing the following labeling  
508 recommendations, which also align with recommendations provided at the 2017 Panel Meeting.  
509 FDA recommends that the bottle’s design include a red cap and red tip as an indication that the  
510 solution should not be instilled directly into the eyes.<sup>16,17</sup> FDA recommends that bottle labeling  
511 consist of three equal-sized panels with a red banner (e.g., at least 1 inch in height) encircling the  
512 top of the bottle that includes text emphasizing that the HPCP solution should not be put into the  
513 eyes. We recommend manufacturers include two identical statements such as “DO NOT PUT IN  
514 EYES,” in emphasized font that span the circumference of the bottle with associated large  
515 graphics (e.g., an image of bottle squirting in the eye crossed out). The red banner on the bottle  
516 labeling should be consistent with the banner on the carton labeling. Please see Appendix C for  
517 an example of the bottle labeling.

518 To minimize overcrowding, the bottle label should include the minimum information needed for  
519 consumers to safely use the product and include the product information, directions for use, and  
520 warnings. The labeling text should be written using clear, simple and concise language. FDA  
521 recommends font sizes consistent with the [Patient Labeling guidance](#). FDA recommends the  
522 bottle labeling contain the following information:

523

#### **a. Manufacturer and product information**

524

- Distributer’s/Manufacturer’s name and address including zip code, phone number

525

- Lot Number

526

- Expiration Date

527

- Date Opened \_\_\_\_/or Discard Date \_\_\_\_\_

528

- Product Trade Name

529

- Description (i.e., Active Ingredients), including emphasis on “3% Hydrogen Peroxide [Solution]” (e.g., in prominent text) located near the Product Trade Name (see [Patient Labeling guidance](#) for recommendations on font sizes for Headings)

530

531

---

<sup>16</sup> March 17, 2017 Meeting: Ophthalmic Devices Panel for the Medical Devices Advisory Committee and the Risk Communication Advisory Committee (available at <https://www.fda.gov/advisory-committees/ophthalmic-devices-panel/2017-meeting-materials-ophthalmic-devices-panel>).

<sup>17</sup> For further information on hydrogen peroxide-based contact lens care products, see <https://www.fda.gov/medical-devices/contact-lenses/hydrogen-peroxide-solution>.

## *Contains Nonbinding Recommendations*

### *Draft – Not for Implementation*

- 532 • Actions and Indications (21 CFR 801.61) (e.g., cleans, disinfects, etc.)
- 533 • Lens Compatibility (i.e., the type of lenses that the HPCP can be used with)
- 534 • Net Quantity Contents (21 CFR 801.62)
- 535 • Sterile
- 536 • Special Storage Conditions (e.g., store at room temperature)
- 537 • A statement advising users to keep out of reach of children
- 538 • A statement referring customers to consult the package insert for complete safety
- 539 information
- 540 • Website and social media connections (e.g., Quick Response (QR) code, website link) to
- 541 manufacturers and FDA (e.g., “Hydrogen Peroxide Solution”
- 542 <https://www.fda.gov/medical-devices/contact-lenses/hydrogen-peroxide-solution>)
- 543

#### **b. Directions for Use**

544  
545 The directions for use should contain the major steps of the process (e.g., rinse with solution, fill  
546 provided container, and soak) as referenced in the package insert. Each step should be briefly  
547 described using simple language for easy understanding. Simple graphics, where appropriate,  
548 should be included to aid in understanding.

#### **c. Contraindications**

549  
550  
551 FDA recommends that all known contraindications specific to the device be included on the  
552 bottle labeling as identified in the package insert section IV.B.1.b of this draft guidance.

#### **d. Warnings**

553  
554  
555 To minimize overcrowding, FDA recommends that manufacturers only include warning  
556 statements that inform the consumer of the risks associated with unneutralized HPCP solution  
557 (e.g., severe burning and stinging) on the bottle labeling. As noted previously, this is important  
558 because unneutralized hydrogen peroxide exposure may result in corneal burns, redness and  
559 stinging. Statements using emphasized text (e.g., red and bold text) should be added to the  
560 warnings section to highlight these concerns and any key details. In addition, clear warnings with  
561 associated graphics should be added to aid in understanding of how consumers may be exposed  
562 to unneutralized hydrogen peroxide. Manufacturers should include the following:

- 563
- 564 • A statement that the solution should only be used with the case provided and warn
- 565 against the use of flat lens cases.
- 566 • A statement identifying the minimum time to ensure the completion of the neutralization
- 567 process prior to lens insertion.
- 568 • A statement that warns against rinsing your lenses with the HPCP solution, which would
- 569 cause severe burning or stinging.
- 570 • A statement that warns against squirting the HPCP solution into the eyes.
- 571 • The statements above, wherever possible, should also warn the consumer of the risks
- 572 associated with inserting HPCP solution into the eye (e.g., severe burning and stinging).
- 573

574

575 **Appendix A: Package Insert Labeling Example**

576

577 This section provides an example of a package insert for an HPCP, as described in Section  
578 IV.B.1.

579

580

581 **GENERAL**

582 Hydrogen peroxide placed directly into the eyes or onto contact lenses prior to insertion  
583 can cause stinging, burning, and transient corneal damage. When using hydrogen  
584 peroxide, the disinfecting process must be followed with neutralization. The  
585 neutralization of hydrogen peroxide into water and oxygen makes it safe to put your  
586 lenses back into the eyes.

587 Neutralization can be either a one-step or two-step process. The one-step process  
588 neutralizes the lenses *during* the disinfecting stage, while the two-step process neutralizes  
589 the lenses *after* the disinfecting stage.

590 Some storage cases have a neutralizer built-in, making it a simple one-step process. With  
591 other cases, a neutralizing tablet that comes with the hydrogen peroxide-based contact  
592 lens care product solution must be added. This is the two-step process.

593 **IMPORTANT** - Please read carefully and keep this information for future use.

594

595 **TRADE NAME**

596 [TRADENAME (TN)]  
597 3% Hydrogen Peroxide Solution

598

599 **DESCRIPTION/CONTENTS:**

600 [Include "sterile;" list active ingredients (optional, list inactive ingredients). When  
601 applicable, include the following additional descriptive information:

602

603 Case, Disk, or Tablet, and describe each item and any additional components]

604

605 **ACTIONS:**

606 [Include a concise description of the function of the device (i.e., how the device works in  
607 relation to the contact lens). When applicable, the actions can be listed with the  
608 indications (i.e., INDICATIONS/ACTIONS).]

609

610 **INDICATIONS (USES):**

611 [Include the Indication for Use Statement as described in the marketing submission.]

612

613 **CONTRAINDICATIONS:**

- 614 • [Include all known contraindications. If there are no known contraindications, add  
615 the statement "There are no known contraindications for use of this product."]  
616 • If you are allergic to any ingredient in this device, DO NOT USE.

*Contains Nonbinding Recommendations*

*Draft – Not for Implementation*

617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635

**GENERAL WARNINGS:**

- **[TN] Solution is neutralized only with the special [TN] Solution case. NEVER use a flat lens case. It will cause severe burning and stinging!**
- **NEVER soak lenses in [TN] Solution for less than [X] hours to ensure completion of the neutralization process prior to lens insertion. It may cause severe burning and stinging. DO NOT PUT [TN] DISINFECTING SOLUTION THAT HAS NOT BEEN NEUTRALIZED IN YOUR EYE. Should unneutralized [TN] solution get in your eye, remove your lenses immediately, flush (wash) your eyes with a large amount of water or sterile saline for a few minutes. If burning and/or irritation persist, seek assistance from an eye care professional.**
- **The red dropper tip indicates that [TN] solution should not be put directly in your eye. DO NOT REUSE NEUTRALIZED HYDROGEN PEROXIDE SOLUTION.**
- **NEVER rinse your lenses with [TN] Solution and put them in your eyes! It will cause severe burning and stinging!**
- **NEVER squirt [TN] Solution into your eyes! It will cause severe burning and stinging!**

636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658

**ADDITIONAL WARNINGS:**

- You should not reuse or “top off” old solution left in your lens case since solution reuse reduces effective lens disinfection and could lead to severe infection, vision loss, or blindness. “Topping off” is the addition of fresh solution to solution that has been sitting in the lens case.
- Do not store your lenses or rinse your lens case with water or any non-sterile or expired saline solution. Use fresh, sterile or unexpired saline solution so you do not contaminate your lenses or lens case. Use of non-sterile or expired solution can lead to severe infection, vision loss, or blindness.
- Water can harbor microorganisms that can lead to severe infection, vision loss, or blindness. If the contact lenses have been exposed to water, such as when showering, swimming in pools, lakes, or oceans, you should discard them and replace them with a new pair. You should ask your eye care professional for recommendations about wearing your lenses during any activity involving water.
- Never use water, saline solution, or rewetting drops to disinfect your lenses. These solutions will not disinfect your lenses. Not using the recommended disinfectant can lead to severe infection, vision loss or blindness.
- Using peroxide solutions beyond the discard date could result in contamination of the solution and can lead to severe infection, vision loss, or blindness.
- To avoid contamination, DO NOT touch tip of container to any surface. Replace cap after using.
- To avoid contaminating your solution, DO NOT transfer to other bottles or containers.

## *Contains Nonbinding Recommendations*

### *Draft – Not for Implementation*

- 659 • Keep out of the reach of children. If accidentally swallowed, an upset stomach and  
660 vomiting may result. Seek immediate professional medical assistance or contact a  
661 poison control center.
- 662 • While rubbing RGP lenses with [TN] solution, some consumers may experience a  
663 mild, temporary skin discoloration (bleaching) of the fingers or hands. Always wash  
664 and rinse your hands after rubbing your lenses with the solution.
- 665 • [When applicable] This tablet is not to be taken internally. If accidentally swallowed,  
666 an upset stomach and vomiting may result. Seek immediate professional medical  
667 assistance or contact a poison control center.
- 668 • [When applicable] DO NOT crush the [TN] Neutralizing Tablet. If a crack occurs in  
669 the coating, the tablet may begin to neutralize the [TN] Disinfecting Solution before  
670 adequate disinfection occurs.
- 671 • [When applicable] DO NOT use [TN] Neutralizer disk for more than [X] uses or [X]  
672 months of daily use. [Note: Uses and time period should be determined by testing  
673 data.]
- 674 • PROBLEMS WITH CONTACT LENSES AND LENS CARE PRODUCTS COULD  
675 RESULT IN SERIOUS INJURY TO THE EYE. Follow your eye care practitioner's  
676 directions and all labeling instructions for proper use and care of your lenses and lens  
677 care products, including the lens case. Eye problems, including corneal ulcers, can  
678 develop rapidly and lead to loss of vision. Daily wear lenses are not indicated for  
679 overnight wear and should not be worn while sleeping. Clinical studies have shown  
680 the risk of serious adverse reactions is increased when these lenses are worn  
681 overnight. Extended wear lenses should be regularly removed for cleaning and  
682 disinfection or for disposal and replacement on the schedule prescribed by your eye  
683 care practitioner. Clinical studies have shown that there is an increased incidence of  
684 serious adverse reactions in extended wear contact lens users as compared to daily  
685 wear contact lens users. Studies have also shown that the risk of serious adverse  
686 reactions increases the longer extended wear lenses are worn before removal for  
687 cleaning and disinfection or for disposal and replacement. Studies have also shown  
688 that smokers who wear contact lenses have a higher incidence of adverse reactions. If  
689 you experience eye discomfort, excessive tearing, vision changes, or redness of the  
690 eye, immediately remove your lenses and promptly contact your eye care practitioner.  
691 All contact lens wearers should see their eye care practitioner as directed.

#### **GENERAL PRECAUTIONS:**

- 694 • Always wash and dry your hands before handling your lenses.
- 695 • DO NOT USE OVER-THE-COUNTER GENERIC HYDROGEN PEROXIDE.  
696 Generic hydrogen peroxide solutions are not intended for ophthalmic use and may  
697 contain ingredients not tested for ocular safety or toxicity. Use of generic hydrogen  
698 peroxide may cause severe burning and stinging if not neutralized before use. In  
699 addition, generic hydrogen peroxide may contain ingredients that cause  
700 DISCOLORATION OR DAMAGE TO YOUR CONTACT LENSES.
- 701 • Do not mix or substitute other hydrogen peroxide-based contact lens care products or  
702 lens cases as inadequate neutralization of hydrogen peroxide may cause severe  
703 burning and stinging.

*Contains Nonbinding Recommendations*

*Draft – Not for Implementation*

- 704 • If lenses are stored for more than 24 hours in [TN] disinfecting solution, disinfect  
705 your lenses again by replacing the solution in the barrel lens case with fresh [TN]  
706 disinfection solution and leave to soak for [X] hours to complete the neutralization  
707 before inserting lenses in the eye.
- 708 • Never reuse the [TN] disinfecting solution. Always discard the remaining solution  
709 from the lens case.
- 710 • Use before the expiration date marked on the carton and bottle. Always use fresh,  
711 unexpired lens care solutions.
- 712 • Do not shake/invert the lens case during the disinfection.
- 713 • Discard contents of the bottle [X] months after first opening.
- 714 • Keep the bottle tightly closed when not in use.
- 715 • Store at [X degrees or specify temperature range].
- 716 • Always keep the lenses completely immersed in the recommended storage solution  
717 when lenses are not being worn (stored). Prolonged periods of drying will damage  
718 lenses/reduce the ability of the lens surface to return to a wettable state.
- 719 • Do not heat the solution and lenses.  
720

**PRECAUTIONS FOR NEUTRALIZING PRODUCTS [WHEN APPLICABLE]:**

- 722 • DO NOT use tablets that appear to be broken, chipped, or discolored.
- 723 • DO NOT use tablets from packages which are torn or punctured.
- 724 • DO NOT substitute [TN] Neutralizer components.
- 725 • DO NOT use neutralizing tablets in a heat disinfection unit.  
726

**ADVERSE REACTIONS (PROBLEMS AND WHAT TO DO):**

**WARNING:**

**EYE PROBLEMS, INCLUDING CORNEAL ULCERS, CAN DEVELOP RAPIDLY AND LEAD TO LOSS OF VISION; IF YOU EXPERIENCE:**

- 731 • Stinging and burning
- 732 • Eye discomfort
- 733 • Excessive tearing
- 734 • Unusual eye secretions
- 735 • Vision changes
- 736 • Loss of vision
- 737 • Eye redness
- 738 • Sensitivity to light (photophobia)
- 739 • Dry eyes
- 740 • Other eye problems

**YOU SHOULD IMMEDIATELY REMOVE THE LENSES, AND PROMPTLY CONTACT YOUR EYE CARE PRACTITIONER.**

- 744 • If you experience stinging and burning, **remove your lenses immediately, flush**  
745 **(wash) your eyes with a large amount of water or sterile saline for a few minutes.**  
746 **If burning and/or irritation persist, seek assistance from an eye care**  
747 **professional.**
- 748 • If the discomfort or problem stops, remove and inspect the lens.

*Contains Nonbinding Recommendations*

*Draft – Not for Implementation*

- 749
- 750
- 751
- 752
- 753
- 754
- 755
- If the lens is in any way damaged, **DO NOT** put the lens back on the eye. Place the lens in the storage case and contact the eye care practitioner.
  - If the lens is not damaged but has dirt, an eyelash, or other foreign body on it, you should thoroughly clean, rinse, and disinfect the lenses; then reinsert them.
  - After reinsertion, if the problem continues, **IMMEDIATELY** remove the lenses and consult the eye care practitioner.

756 If any of the above symptoms occur, a serious condition such as infection, corneal ulcer,  
757 neovascularization or iritis may be present. Seek immediate professional identification of  
758 the problem and prompt treatment to avoid serious eye damage.

759 All adverse reactions observed while using [TN] should be reported to:

761 [Manufacturer's Name]  
762 [Manufacturer's Address]  
763 [Manufacturer's Website]  
764 [U.S.-Based Toll Free Telephone Number]

765 and can also be reported to FDA MedWatch,  
766 <https://www.accessdata.fda.gov/scripts/medwatch/index.cfm>.

767

768

769

770 **GENERAL DIRECTIONS FOR USE:**

- 771
- 772
- 773
- 774
- 775
- 776
- 777
- 778
- Always wash and rinse your hands before handling your lenses. This will help to prevent eye infections by removing dirt and oils that could get on the lenses.
- 1) Place lenses in holder of special [TN] Solution case. Squirt some solution over them.
  - 2) Fill the special [TN] Solution case up to the fill line. Put the lens holder in the case. Tighten the cap on the [TN] Solution case.
  - 3) Soak the lenses in the special [TN] Solution case for a minimum of [X] hours. Your lenses are ready to wear after soaking for at least [X] hours.

779 ***DIRECTIONS FOR USE - Soft Lenses:***

780 **Do not put [TN] solution on your lenses and insert directly into the eye or burning**  
781 **and stinging will result.**

782 **TO CLEAN, DISINFECT, AND NEUTRALIZE YOUR LENSES:**

- 783
- 784
- 785
- 786
- 787
- 788
- Remove and place each lens into the appropriately marked L/R domed lens holder.
  - [Specify the total rinse time, in addition to stating the minimum lens rinsing time for each side of the lens. In addition to your directions that state to rinse the lenses for x seconds each, you should also state that the rinse time is “for a total of [X] seconds”.]

## *Contains Nonbinding Recommendations*

### *Draft – Not for Implementation*

- 789           ○ Fill the lens case to fill line with [TN] solution and place the lens holder in the  
790           case.
- 791           ○ Tighten the cap and store lenses for at least [insert recommended duration] hours  
792           or overnight. **DO NOT SHAKE THE CASE.** NOTE: To prevent damage to your  
793           lens, center the lens on the dome in the lens holder. Be sure the lens does not  
794           touch the basket rim, then close the basket lid.
- 795           ○ After soaking for [insert recommended duration] hours, your lenses are ready to  
796           wear. **Never rinse your lenses with [TN] solution prior to insertion or burning**  
797           **and stinging will result.** If desired, lenses can be rinsed with sterile saline before  
798           inserting.
- 799           ○ Discard the neutralized disinfectant from the cup. Rinse the lens cup with fresh  
800           saline or [TN] solution and allow the case to air dry with the lens holder inverted  
801           outside the case. Do not place the lens holder on its side.

802  
803  
804           Your eye care professional may recommend additional products or procedures to care for  
805           your lenses based on individual tear chemistry and lens wearing schedule. Always follow  
806           your eye care professional's instructions. Seek advice from your eye care professional  
807           before making changes to your care regimen to ensure compatibility with lenses.

#### ***DIRECTIONS FOR USE – RGP Lenses:***

808  
809  
810           **Do not put [TN] solution on your lenses and insert directly into the eye or burning**  
811           **and stinging will result.**

- 812  
813           ○ Remove your lenses one at a time and place them into the appropriately marked  
814           dome basket holder.
- 815           ○ Place each lens in the palm of your hand, apply 2 to 4 drops of [TN] solution and  
816           rub. While rubbing your lenses with [TN] solution, some users may experience a  
817           mild, temporary skin discoloration (bleaching) of the fingers or hands. Always  
818           wash and rinse your hands after rubbing your lenses with the solution.
- 819           ○ Return the lenses to the appropriate holder and close the baskets. Thoroughly  
820           rinse the lenses for [insert recommended duration] seconds through the basket  
821           with [TN] solution.
- 822           ○ Fill the lens case with [TN] solution and place the lens holder in the case. Tighten  
823           the cap and store lenses for at least [insert recommended duration] hours. **DO**  
824           **NOT SHAKE THE CASE.** Do not rinse the lenses. Place the lenses directly on  
825           the eye from the solution or place a few drops of a contact lens rewetting drop on  
826           the lens for extra cushioning.

827           Your eye care professional may recommend additional products or procedures to care  
828           for your lenses based on individual tear chemistry and lens wearing schedule. Always

*Contains Nonbinding Recommendations*

*Draft – Not for Implementation*

829 follow your eye care professional’s instructions. Seek advice from your eye care  
830 professional before making changes to your care regimen to ensure compatibility with  
831 lenses.

832 **LENS CASE CARE**

- 833 • Rinse your lens case with sterile or unexpired contact lens solution (never use tap  
834 water) and leave the lens case open to dry after each use. Turn the case over and shake  
835 any excess solution out of the case. Be sure that no residual solution remains in the  
836 case before you allow it to air dry.
- 837 • Replace your lens case every [insert a recommended time period]. Contact lens cases  
838 can be a source of bacterial growth.

839  
840 **HOW SUPPLIED:**

841 [Describe how device is packaged for distribution (e.g., quantity of contents, sterile,  
842 packaged in bottle, and marked with lot number and expiration date).]

843  
844 **MANUFACTURER OR DISTRIBUTOR NAME AND ADDRESS:**

845 [Include the information that expresses the following information: [Distributed  
846 by/Manufactured by/Manufactured for] Address including zip code, and Manufacturer’s  
847 website.]

848  
849 **PRINTED [MONTH AND YEAR]**

850

## 851 **Appendix B: Carton Labeling Example**

852  
853 This section provides an example of carton labeling for an HPCP containing important product  
854 information, warnings, and precautions, as described in Section IV.B.2.  
855

### 856 857 **PRODUCT INFORMATION:**

#### 858 **Principal Display Panel:**

- 859 • [Product Trade Name, including emphasis on “3% Hydrogen Peroxide [Solution]”  
860 (e.g., in prominent text) (see [Patient Labeling guidance](#) for recommendations on font  
861 sizes for Headings)]
- 862 • [Actions and Indications (21 CFR 801.61) (e.g., cleans, disinfects)]
- 863 • [Lens Compatibility (i.e., the type of lenses for which the device may be used)]
- 864 • [Net Quantity Contents (21 CFR 801.62)]
- 865 • [Sterile]

#### 866 867 **Outer Carton Panels:**

- 868 • [Special Storage Conditions (e.g., store at room temperature)]
- 869 • [A statement referring customers to the bottle and package insert for information on  
870 proper use of the product]
- 871 • [A statement advising users to keep out of reach of children]
- 872 • [Tamper-Resistant Statement (21 CFR 800.12)]
- 873 • [Insert information on whom to contact for concerns, adverse reactions, and  
874 additional information: [Distributed by/Manufactured by/Manufactured for] Address  
875 including zip code, website, and phone number.]
- 876 • [Lot Number]
- 877 • [Expiration Date]
- 878 • Product Information:
  - 879 ○ [Description (i.e., Active Ingredients)]
  - 880 ○ [Package contents (e.g., a lens case is included)]
- 881 • [A statement referring customers to consult the package insert for complete safety  
882 information]
- 883 • [Website and social media connections (e.g., Quick Response (QR) code, website  
884 link) to manufacturers and FDA (e.g., “Hydrogen Peroxide Solution”  
885 <https://www.fda.gov/medical-devices/contact-lenses/hydrogen-peroxide-solution>)]

### 886 887 **CONTRAINDICATIONS:**

- 888 • [Include all known contraindications. If there are no known contraindications, add  
889 the statement “There are no known contraindications for use of this product.”]
- 890 • If you are allergic to any ingredient in this device, DO NOT USE.

### 891 892 **WARNINGS:**

## *Contains Nonbinding Recommendations*

### *Draft – Not for Implementation*

- 893
- 894
- 895
- 896
- 897
- 898
- 899
- 900
- 901
- 902
- [TN] Solution is neutralized only with the special [TN] Solution case. NEVER use a flat lens case. It will cause severe burning and stinging!
  - NEVER soak lenses in [TN] Solution for less than [X] hours. It may cause severe burning and stinging!
  - NEVER rinse your lenses with [TN] Solution and put them in your eyes! It will cause severe burning and stinging!
  - NEVER squirt [TN] Solution into your eyes! It will cause severe burning and stinging!
  - **Contains Hydrogen Peroxide**, To avoid injury, follow all directions on the bottle and package insert.

#### **Top Left and Right Carton Flaps** [in emphasized (e.g., bold, red) text]

903

904

905

906

907

908

Left Flap: [A schematic of a flat lens case, encircled with a line through it, with the accompanying verbiage in bold type: “DO NOT USE FLAT LENS CASE.”]

909

910

Right Flap: [A schematic of your lens case, with the accompanying verbiage in bold type: “USE ONLY THE [TN] LENS CASE PROVIDED.”]

#### **PRECAUTIONS:**

- 911
- 912
- 913
- 914
- 915
- 916
- 917
- 918
- **DO NOT USE OVER-THE-COUNTER GENERIC HYDROGEN PEROXIDE.** Generic hydrogen peroxide solutions are not intended for ophthalmic use and may contain ingredients not tested for ocular safety or toxicity. Use of Generic hydrogen peroxide may cause severe burning and stinging if not neutralized before use.
  - Do not mix or substitute other hydrogen peroxide-based lens care products or lens cases as inadequate neutralization of peroxide may cause severe burning and stinging.

Contains Nonbinding Recommendations

Draft – Not for Implementation

919 **Appendix C: Sample Bottle Labeling**

920 This section provides an example of bottle labeling for an HPCP solution that contains important  
921 warnings and directions for use as well as relevant product information, as described in Section  
922 VI.B.3.

923 **Figure 1: Example of Bottle Labeling**

925

**DO NOT PUT IN EYES** **DO NOT PUT IN EYES**

**DIRECTIONS FOR USE:**

1. Place lenses in holder of special [TN] Solution case. Squirt some solution over them.
2. Fill the special [TN] Solution case up to the fill line. Put the lens holder in the case. Tighten the cap on the [TN] Solution case.
3. Soak the lenses in the special [TN] Solution case for a minimum of 6 hours.

**YOUR LENSES ARE READY TO WEAR AFTER SOAKING FOR AT LEAST 6 HOURS.**

**Trade Name [TN] SOLUTION**  
3% Hydrogen Peroxide

**[MANUFACTURER and PRODUCT INFORMATION]**  
**[CONTRAINDICATIONS (if applicable)]**

**WARNING!**

1. [TN] Solution is neutralized only with the [TN] Solution Case. NEVER use a flat lens case. It will cause severe burning and stinging!
2. NEVER soak lenses in [TN] Solution for less than 6 hours. It may cause severe burning and stinging!
3. NEVER rinse your lenses with [TN] Solution and put them in your eyes! It will cause severe burning and stinging!
4. NEVER squirt [TN] Solution into your eyes! It will cause severe burning and stinging!

926

927

928 **MANUFACTURER and PRODUCT INFORMATION:**

- 929
- [Distributor’s/Manufacturer’s name and address including zip code, phone number]
  - [Lot Number]
  - [Expiration Date]
  - [Date Opened \_\_\_\_/or Discard Date \_\_\_\_]
  - [Product Trade Name]
  - [Description (i.e., Active Ingredients), including emphasis on “3% Hydrogen Peroxide [Solution]” (e.g., in prominent text) located near the Product Trade Name (see [Patient Labeling guidance](#) for recommendations on font sizes for Headings)]
  - [Actions and Indications (21 CFR 801.61) (e.g., cleans, disinfects, etc.)]
  - [Lens Compatibility (i.e., the type of lenses for which the device may be used)]
  - [Net Quantity Contents (21 CFR 801.62)]
  - Sterile
  - [Special Storage Conditions (e.g., store at room temperature)]
  - [A statement advising users to keep out of reach of children]
- 930
- 931
- 932
- 933
- 934
- 935
- 936
- 937
- 938
- 939
- 940
- 941
- 942

*Contains Nonbinding Recommendations*

*Draft – Not for Implementation*

- 943
- [A statement referring customers to consult the package insert for complete safety information]
  - [Website and social media connections (e.g., Quick Response (QR) code, website link) to manufacturers and FDA (e.g., “Hydrogen Peroxide Solution” <https://www.fda.gov/medical-devices/contact-lenses/hydrogen-peroxide-solution>) ]
- 944
- 945
- 946
- 947
- 948

949 **DIRECTIONS FOR USE:**

950

- 951
- 1) Place lenses in holder of special [TN] Solution case. Squirt some solution over them.
  - 952 2) Fill the special [TN] Solution case up to the fill line. Put the lens holder in the case.  
953 Tighten the cap on the [TN] Solution case.
  - 954 3) Soak the lenses in the special [TN] Solution case for a minimum of [X] hours. Your  
955 lenses are ready to wear after soaking for at least [X] hours.

956 **CONTRAINDICATIONS:**

- 957
- [Include all known contraindications. If there are no known contraindications, add the statement “There are no known contraindications for use of this product.”]
  - 958 • If you are allergic to any ingredient in this device, DO NOT USE.
- 959
- 960

961 **WARNINGS:**

- 962
- [TN] Solution is neutralized only with the [TN] Solution case. NEVER use a flat lens case. It will cause severe burning and stinging.
  - 963 • NEVER soak lenses in [TN] Solution for less than [X] hours. It may cause severe  
964 burning and stinging.
  - 965 • NEVER rinse your lenses with [TN] Solution and put them in your eyes! It will cause  
966 severe burning and stinging!
  - 967 • NEVER squirt [TN] Solution into your eyes! It will cause severe burning and  
968 stinging!
  - 969

970